10 results about "Specific antibody level" patented technology

The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.

The present invention relates to the use of mesenchymal stem cells (MSCs) for enhancing the immune response of elderly or animal subjects to vaccination. According to the application, the defects of spleen stromal cell networks and lymphocyte structures of old subjects can be repaired by applying the MSC in advance, and the immune level of organisms is improved; and the vaccine is injected after a period of time, so that the specific antibody level after vaccine immunization can be improved. The effect can also significantly prevent the elderly subjects from being infected by influenza. Therefore, the MSC has a good application prospect in solving related immune decline of old people.

The invention discloses clostridium butyricum, a clostridium butyricum preparation for preventing and controlling African swine fever virus and application of the clostridium butyricum preparation, and belongs to the technical field of microorganisms. The clostridium butyricum JBH-KOLONIZER BD-10 serving as a fermentation strain is preserved in the China Center for Type Culture Collection, and the preservation number of the clostridium butyricum JBH-KOLONIZER BD-10 is CCTCC (China Center for Type Culture Collection) NO: M 20231636. The clostridium butyricum fermentation liquor disclosed by the invention has an obvious inhibition effect on the replication of the African swine fever virus. The clostridium butyricum is used as a fermentation strain to prepare the clostridium butyricum microbial preparation, and the clostridium butyricum microbial preparation is added into pig complete feed, so that African swine fever virus replication can be effectively inhibited, oxidative stress can be relieved, the non-specific antibody level of weaned piglets can be improved, and pig herd health can be promoted. In addition, the clostridium butyricum preparation is free of drug resistance and toxic and side effects after being applied to swinery and has the advantages of being low in cost, high in safety and environmentally friendly.

The invention relates to a method to measure the level of HSV1-specific antibodies in a biological sample, and methods to stratify herpes simplex encephalitis patients according to their risk of developing autoimmune anti-NMDA-receptor encephalitis. The invention further encompasses pharmaceutical formulations, and methods of treatment useful for treating encephalitis patients.

The invention discloses application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating antibody-mediated rejection reaction, and belongs to the technical field of biological medicine. According to the application, an acute antibody-mediated rejection reaction model of mouse skin pre-sensitization combined with kidney transplantation is constructed, and alpha-KG is applied for intervention. Results show that the alpha-KG can significantly improve renal functions (serum creatinine and urea nitrogen are reduced), prolong survival time of the transplanted kidney, relieve histological injury of the transplanted kidney (Banff score is reduced), inhibit deposition of complement C3d, reduce the level of a specific antibody (DSA) of a peripheral blood donor, down-regulate expression of kidney local inflammatory factors (Tnf, Il-6, Il-1beta and Nos2), regulate immune cell infiltration in the transplanted kidney, and improve the survival rate of the transplanted kidney. Comprising the steps of reducing transplantation kidney mononuclear / macrophage infiltration, reducing the proportion of transplantation kidney pro-inflammatory macrophages and increasing the proportion of repair macrophages. The application provides a new drug choice for treating the acute antibody-mediated rejection of the transplanted kidney, and has an important clinical application prospect.

The application discloses a use of ursolic acid as a SARS-CoV-2 subunit vaccine adjuvant, aims to solve the technical problems of relatively weak immunogenicity of existing subunit vaccines, possible local or systemic adverse reactions of some adjuvants and unclear action mechanism, and provides a new medical use of ursolic acid. The ursolic acid can effectively improve the antigen-specific antibody level of the subunit vaccine immunized mice, promote the formation of germinal centers and enhance follicular helper T cell response. The action mechanism is that after the ursolic acid is combined with PTPRF, the stability of the PTPRF is affected and the degradation of the PTPRF is promoted, thereby enhancing the downstream STAT3 phosphorylation, promoting the expression of antigen presentation related genes and improving the antigen presentation ability of the dendritic cells, and finally enhancing the antibody response of the body. The application provides a new subunit vaccine adjuvant candidate molecule for preventing severe SARS-CoV-2 related infections in clinic, and provides a new molecular target and mechanism basis for the development of subunit vaccine adjuvants.

The invention discloses a mineralized foot-and-mouth disease virus-like particle hydrogel vaccine as well as a preparation method and application thereof. The hydrogel vaccine is obtained by taking a mixture of hyaluronic acids with medium, high and low molecular weights as a carrier and entrapping calcium phosphate mineralized foot-and-mouth disease virus-like particles. The safety of the hydrogel vaccine is comprehensively evaluated through in-vivo and in-vitro experiments, and the result shows that the hydrogel vaccine constructed by the invention has excellent biocompatibility. Meanwhile, the hydrogel vaccine shows excellent antigen slow release ability, can induce generation of a specific antibody level equivalent to that of a VLPs-CaP vaccine compatible with an ISA201 adjuvant, and can also significantly improve the expression level of surface molecules of lymphatic B cell memory and T cell memory. The results show that the hydrogel vaccine constructed by the invention can induce excellent humoral immune response, cellular immune response and immune memory level, and has a good application prospect in the field of veterinary vaccines.

The invention relates to the technical field of biological medicines, and particularly discloses a vaccine adjuvant composition as well as a preparation method and application thereof. The vaccine immune composition provided by the invention comprises GM-CSF and cortex albiziae saponin, and has the following advantages: 1, the vaccine immune composition can significantly improve the specific antibody level and the cytokine secretion efficiency, effectively promote the activation of killer T cells, efficiently induce the response of memory T cells, and construct a stable immune defense basis; 2, the immune level of the organism can be remarkably improved after challenge, the tissue injury risk is reduced by inhibiting replication and colonization of viruses in key target organs, and meanwhile, the body weight of the organism is promoted to be quickly recovered after challenge, so that the physiological homeostasis of the organism is better maintained; thirdly, the method is wide in adaptability and can be compatible with various veterinary vaccines such as foot-and-mouth disease vaccines, porcine reproductive and respiratory syndrome vaccines, pseudorabies vaccines and porcine circovirus type 2 vaccines. The method can be applied to the fields of research, development and preparation of vaccine adjuvants or vaccines and the like.

The application belongs to the technical field of biology and discloses a fusion protein S1-linker-Ferritin nanoparticle, wherein the fusion protein S1-linker-Ferritin nanoparticle comprises S1 protein of porcine epidemic diarrhea virus, a ferritin linker and Ferritin protein; the nucleotide sequence of the fusion protein S1-linker-Ferritin nanoparticle is shown in SEQ ID NO. 1, and the amino acid sequence is shown in SEQ ID NO. 2; the fusion protein S1-linker-Ferritin nanoparticle is prepared into a vaccine, and the specific IgG antibody level and the neutralizing antibody level of mice immunized by the vaccine are higher than those of mice immunized by a commercial inactivated vaccine (p<0.01), the number of CD3 + CD4 + , CD3 + CD8 + T cells produced by the mice immunized by the vaccine are higher than those of the mice immunized by the commercial inactivated vaccine. Meanwhile, the application discloses a preparation method of the fusion protein S1-linker-Ferritin nanoparticle and a vaccine containing the fusion protein S1-linker-Ferritin nanoparticle.

This invention discloses an injectable composite hydrogel adjuvant, its preparation method, and its application. The composite hydrogel adjuvant is formed by conjugating the TLR receptor 7 agonist Gardimquid to chitosan oligosaccharide, and then adding the Gardimquid-conjugated chitosan oligosaccharide to an oxidized hyaluronic acid solution, forming a stable gel through chemical cross-linking. This composite hydrogel adjuvant is loaded with calcium phosphate-mineralized type O foot-and-mouth disease virus-like particles to form a hydrogel vaccine. Experimental results show that the vaccine has excellent biocompatibility, recruiting 16.12% dendritic cells and 9.62% macrophages (antigen-presenting cells), and has the ability to enhance antigen migration and uptake, and promote immune cell activation. Furthermore, it can induce sustained and potent levels of specific antibodies and cellular immunity, and maintain immune memory for 20 weeks. This invention provides an effective technical means to improve the duration of immunity from foot-and-mouth disease virus-like particles, enhance the immunization effect, and achieve single-dose immunization.